Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3675
Structure:
Synonyms:
1-Hydrazino-2-phenylethane
2-Phenethylhydrazine
2-Phenylethylhydrazine
4-15-00-01269 (Beilstein Handbook Reference)
51-71-8
AB00053520
AC1L1GGN
AKOS000131105
BBV-011834
beta-Phenylethylhydrazine
BPBio1_000043
BRD-K87024524-065-05-2
BRN 0742354
BSPBio_000039
BSPBio_002373
C07430
C8H12N2
CAS-156-51-4
CBChromo1_000176
CCG-205051
CHEBI:248018
CHEMBL1089
cMAP_000003
CPD001496977
D08349
DB00780
DivK1c_000062
EINECS 200-117-9
Fenelzin
Fenelzina
Fenelzina [INN-Spanish]
Fenelzyna
Fenelzyna [Polish]
Fenelzyne
Fenelzyne [Polish]
HMS3259L04
Hydrazine, (2-phenylethyl)-
HYDRAZINE, PHENETHYL-
IDI1_000062
KBio1_000062
KBio2_001331
KBio2_002265
KBio2_003899
KBio2_004833
KBio2_006467
KBio2_007401
KBio3_001593
KBio3_002745
KBioGR_000950
KBioGR_002265
KBioSS_001331
KBioSS_002266
Lopac-P-6777
Lopac0_000971
LS-76934
MLS000758253
Nardil
NCGC00015830-01
NCGC00015830-02
NCGC00015830-03
NCGC00015830-04
NCGC00015830-05
NCGC00162301-01
NINDS_000062
Phenelezine
Phenelzine
Phenelzine (BAN)
Phenelzine sulfate
Phenelzine [INN:BAN]
Phenelzinum
Phenelzinum [INN-Latin]
Phenethylhydrazine
Phenylethyl hydrazine-HCl
Phenylethylhydrazine
Prestwick0_000170
Prestwick1_000170
Prestwick2_000170
Prestwick3_000170
SAM002589985
SMR000058500
SPBio_001137
SPBio_001960
Spectrum2_001009
Spectrum3_000677
Spectrum4_000475
Spectrum5_000990
Spectrum_000851
Stinerval
UNII-O408N561GF
W 1544-A
W1544
ATC-Codes:
Side-Effects:
Side-EffectFrequency
euphoria0
psychosis0
shock0
vomiting0
nystagmus0
convulsions0
sweating0
insomnia0
tachycardia0
glaucoma0
urinary retention0
nausea0
manic0
hypernatremia0
leukopenia0
headache0
metabolic acidosis0
somnolence0
malaise0
tremor0
delirium0
jaundice0
postural hypotension0
blurred vision0
fever0
coma0
schizophrenia0
paresthesia0
weakness0
constipation0
agitation0
rash0
nightmares0
lupus0
fatigue0
dry mouth0
hypoxia0
pruritus0
impotence0
hypersomnia0
edema0
ataxia0
dizziness0
weight gain0

Target

show target details
Uniprot ID:A4TB13_MYCGI
Synonyms:
Amine oxidase (Copper-containing)
EC-Numbers:1.4.3.6
Organism:Mycobacterium flavescens (strain ATCC 700033 / PYR-GCK
Mycobacterium gilvum
strain PYR-GCK
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----

References:

18539478
Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors.. C Carpéné; V Abello; Z Iffiú-Soltész; N Mercier; Bruno Fève; P Valet (2008) Pharmacological research : the official journal of the Italian Pharmacological Society display abstract
Inhibition of semicarbazide-sensitive amine oxidases (SSAO) and monoamine oxidases (MAO) reduces fat deposition in obese rodents: chronic administration of the SSAO-inhibitor semicarbazide (S) in combination with pargyline (MAO-inhibitor) has been shown to reduce body weight gain in obese Zucker rats, while (E)-2-(4-fluorophenethyl)-3-fluoroallylamine, an SSAO- and MAO-B inhibitor, has been reported to limit weight gain in obese and diabetic mice. Our aim was to state whether such weight gain limitation could occur in non-obese, non-diabetic rats and to extend these observations to other amine oxidase inhibitors. Prolonged treatment of non-obese rats with a high dose of S (900 micromol kg(-1) day(-1)) reduced body weight gain and limited white adipose tissue enlargement. When chronically administered at a threefold lower dose, S also inhibited SSAO activity but not fat depot enlargement, suggesting that effects other than SSAO inhibition were involved in adipose tissue growth retardation. However, combined treatment of this lower dose of S with pargyline inhibited SSAO, MAO, energy intake, weight gain and fat deposition. Adipocytes from treated rats exhibited unchanged insulin responsiveness but impaired antilipolytic responses to amine oxidase substrates. Phenelzine clearly inhibited both MAO and SSAO when tested on adipocytes. Obese rats receiving phenelzine i.p. at 17 micromol kg(-1) day(-1) for 3 weeks, exhibited blunted MAO and SSAO activities in any tested tissue, diminished body weight gain and reduced intra-abdominal adipose tissue. Their adipocytes were less responsive to lipogenesis activation by tyramine or benzylamine. These observations suggest that SSAO inhibition is not sufficient to impair fat deposition. However, combined MAO and SSAO inhibition limits adiposity in non-obese as well as in obese rats.
8694842
Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives.. J M Lizcano; A Fernández de Arriba; K F Tipton; M Unzeta (1996) Biochemical pharmacology display abstract
Microsomal semicarbazide-sensitive amine oxidase (SSAO) from bovine lung was shown to be inhibited by a number of hydrazine derivatives, but the mechanisms of inhibition were found to differ. Hydralazine behaved as an irreversible and partially time-dependent inhibitor with an IC50 value of 1 microM under the conditions used. Phenylhydrazine was found to be a potent irreversible inhibitor of SSAO (IC50 30 nM). Semicarbazide behaved as a specific irreversible inhibitor (active-site-directed irreversible inhibitor) in first forming a non-covalent enzyme-semicarbazide complex (with a Ki value of 85 microM), which then reacted to give an irreversibly inhibited enzyme species in a reaction defined by the first-order rate constant k2 = 0.065 min-1. Phenelzine behaved as a reversible inhibitor, but dialysis at 37 degrees C was found to be necessary to obtain full recovery of enzyme activity. The dependence of inhibition on phenelzine concentration was complex and consistent with multiple binding sites for this inhibitor. This diversity in the action of a family of compounds with the same functional group must be taken into account in attempts to design more specific inhibitors of this enzyme.